Table 2 Replication and pooled analysis of the association between ARMS2/HTRA1 rs10490924 and additional treatment requirement after 3 monthly injections of ranibizumab.

From: A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration

Stage

1/2

Additional treatment (−) (11/12/22)

Additional treatment ( + ) (11/12/22)

OR (95% CI)

P

OR (95% CI)*

P*

Discovery stage

G/T

27/25/21

26/72/69

0.50 (0.20–0.34)

0.00053

0.55 (0.32–0.81)

0.0023

Replication stage

G/T

15/27/15

22/57/50

0.64 (0.41–1.00)

0.051

0.72 (0.46–1.12)

0.14

Pooled analysis

G/T

42/52/36

48/129/119

0.57 (0.42–0.76)

0.00014

0.63 (0.47–0.83)

0.0013

  1. *Adjusted for age and sex, OR: odds ratio, CI: confidence interval.
Back to article page